Stroke clinical trials, in English

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine the ability of combined anatomical and functional cardiac CT imaging to improve morbidity and mortality in patients with suspected or known ischemic heart disease.

NCT04709900 · Official ClinicalTrials.gov record · Copenhagen University Hospital, Rigshospitalet

The goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.

NCT04971564 · Official ClinicalTrials.gov record · Fondation Ophtalmologique Adolphe de Rothschild

Background: CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy) is a genetic disorder. It causes narrowing of the small blood vessels and can lead to strokes and dementia.

NCT05072483 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)

The goal of this clinical trial is to measure the how well it works of a musical interventionand non-invasive brain stimulation in neurological patients. The main questions it aims to answer are: * to measure the residual neuroplastic processes in DOC state related to music exposure * to determine the putative modulation of the aforementioned processes and the clinical outcome of DOC patients by non-pharmacological strategies, i.e., electric (tDCS) and music stimulation * to measure the impact of this intervention on caregiver's burden and psychological distress.

NCT05706831 · Official ClinicalTrials.gov record · Istituti Clinici Scientifici Maugeri SpA

REACT-AF is a multicenter prospective, randomly assigned, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

NCT05836987 · Official ClinicalTrials.gov record · Johns Hopkins University

This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer. This technology is named MindEx (for Mind Extender).

NCT05936619 · Official ClinicalTrials.gov record · Nader Pouratian

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF.

NCT05976685 · Official ClinicalTrials.gov record · Insel Gruppe AG, University Hospital Bern

Atrial fibrillation is a cardiac arrhythmia most often originating in the left atrium, causing anarchic electrical activity and thus a loss of atrial contraction. This increases the risk of stroke through clot formation in the atrium, but also of heart failure.

NCT06047782 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire Dijon

Cardiovascular disease (for example, heart attack, stroke, heart failure) is the commonest complication of kidney failure. Kidney transplantation reduces cardiovascular risk but cardiovascular disease remains the commonest cause of death in patients following transplantation.

NCT06234410 · Official ClinicalTrials.gov record · University of Edinburgh

Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke.

NCT06352632 · Official ClinicalTrials.gov record · The George Institute

For patients with acute ischemic stroke caused by large vessel occlusion, endovascular thrombectomy has been demonstrated to be the most effective therapy, as approximately 90% of the occluded vessels can be recanalized. However, less than 50% of patients could achieve functional independence, and over 15% died 90 days after stroke.

NCT06559241 · Official ClinicalTrials.gov record · Capital Medical University

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital.

NCT06578195 · Official ClinicalTrials.gov record · St. Joseph's Hospital and Medical Center, Phoenix

The goal of this clinical trial is to obtain initial feedback on the implementation of the STRATIF-AI platform and digital twin in the secondary prevention phase in patients with stroke, Moyamoya disease and Cerebral amyloid angiopathy, including adults of both sexes. The main questions it aims to answer is: how is the patients' experience regarding the use of the STRATIF-AI platform?

NCT06714097 · Official ClinicalTrials.gov record · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

The present project aims to measure the facilitatory modulation of motor responses of the limb upper limb by tsDCS in patients with arm/hand hyposthenia after cerebral ischemia to verify the possible therapeutic benefits that this type of stimulation can induce in terms of of strength, dexterity and effectiveness in acts of daily living.

NCT06826274 · Official ClinicalTrials.gov record · IRCCS San Raffaele Roma

This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT). IVT is a common emergency treatment for stroke, but current guidelines say it should not be given to people who have taken FXa inhibitors in the last 48 hours.

NCT06878066 · Official ClinicalTrials.gov record · Guri Hagberg

The aim of the study is to test the effect of tDCS stimulation on upper and lower limb function in neurological patients and to reduce pain in gynaecological patients. And the impact of tDCS stimulation on patients' quality of life.

NCT06891690 · Official ClinicalTrials.gov record · Poznan University of Physical Education

The postulate of this study is that rehabilitation combining linguistic and metacognitive training will result in a significant improvement in language performance correlated with changes in functional cerebral connectivity networks. In addition, it could potentiate the generalisation of effects to verbal and non-verbal communication skills, having a direct impact on patients' quality of life.

NCT06930131 · Official ClinicalTrials.gov record · University Hospital, Toulouse

The aim of this study is to measure the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.

NCT06951867 · Official ClinicalTrials.gov record · AstraZeneca

The goal of this clinical trial is to investigate motor responses in healthy subjects and patients with movement disorders, brain and spinal cord injury, neuromuscular diseases, or cardiovascular diseases. This study aims to measure the effectiveness of traditional physical activities combined with innovative interventions such as cryotherapy, ultrasound therapy, laser therapy, transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS).

NCT07066137 · Official ClinicalTrials.gov record · IRCCS Centro Neurolesi Bonino Pulejo

This study seeks to provide high-quality evidence on the potential benefits of the dual stentriever approach, potentially informing future clinical guidelines and improving outcomes in patients with anterior circulation large vessel occlusion strokes.

NCT07113184 · Official ClinicalTrials.gov record · Instituto de Investigación Marqués de Valdecilla

This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly.

NCT07175428 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

The two most common causes of brain injury are stroke and trauma. Both sleep and mental health problems are common after brain injury; we will see if there is a relationship between poor sleep quality and worse mental health in this group.

NCT07215195 · Official ClinicalTrials.gov record · University of Oxford

This study wants to examine the feasibility and effectiveness of a novel, multimodal approach that combines passive devices with noninvasive neuromuscular stimulation for upper extremity rehabilitation after stroke.

NCT07218276 · Official ClinicalTrials.gov record · University of Michigan

The VOICE Study is an early feasibility study to measure the initial clinical safety and how well it works of the N1 and R1 Systems device design concept in providing an ability to communicate. The Neuralink N1 Implant is intended to provide the ability to communicate to individuals with severe and irreversible speech production impairment.

NCT07224256 · Official ClinicalTrials.gov record · Neuralink Corp

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 90 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.

NCT07227246 · Official ClinicalTrials.gov record · Joseph Broderick, MD

This study wants to measure cardiovascular outcomes with orforglipron compared with dummy treatment (placebo) in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

NCT07241390 · Official ClinicalTrials.gov record · Eli Lilly and Company

Spasticity is an umbrella term for impairments of muscle tone and control in people with damage to the brain and spinal cord. It is highly prevalent and results in pain, stiffness, and contribute to difficulties in activities of daily living.

NCT07303582 · Official ClinicalTrials.gov record · Oxford University Hospitals NHS Trust

Exercise has shown multiple beneficial effects in both healthy and post-stroke populations. One of these is the acute reduction in sensitivity to painful stimuli, called exercise-induced hypoalgesia (EIH).

NCT07327593 · Official ClinicalTrials.gov record · Neuron, Spain

The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one treatment case. The study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.

NCT07349121 · Official ClinicalTrials.gov record · Boston Scientific Corporation

This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study.

NCT07361302 · Official ClinicalTrials.gov record · Boehringer Ingelheim

This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.

NCT07430956 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

The goal of this clinical trial is to measure the safety and preliminary how well it works of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices.

NCT07521930 · Official ClinicalTrials.gov record · Johns Hopkins University

This study wants to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; pulmonary vein isolation \[PVI\] and superior vena cava isolation \[SVCI\]), with or without another technique called posterior wall isolation (PWI).

NCT07527299 · Official ClinicalTrials.gov record · Biosense Webster, Inc.

The goal of this clinical trial is to measure the how well it works and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in patients with acute ischemic stroke (AIS) guided by DWI-FLAIR mismatch on MRI. The main questions it aims to answer are: 1.

NCT07540416 · Official ClinicalTrials.gov record · The First Affiliated Hospital of Zhengzhou University

The goal of this clinical trial is to learn whether pemafibrate can help prevent worsening of intracranial arterial stenosis (ICAS) in patients who have symptomatic ICAS and high triglycerides (TG) levels after ischemic stroke or transient ischemic attack (TIA). The main questions this study aims to answer are: 1.

NCT07562178 · Official ClinicalTrials.gov record · Tokyo Women's Medical University

Carotid angioplasty and stenting (CAS) is an effective treatment for carotid artery stenosis but carries a risk of cerebral embolization. This prospective randomly assigned study evaluates the safety and how well it works of proximal embolic protection using a balloon guide catheter during CAS by comparing the incidence of diffusion-weighted MRI-detected microembolisms and symptomatic thromboembolic events between protected and unprotected procedures.

NCT07576790 · Official ClinicalTrials.gov record · Instituto de Investigación Marqués de Valdecilla

Non-invasive, non-pharmaceutical technologies that augment routine clinical practice for brain diseases and manage chronic symptoms have advanced rapidly over the past two decades. Among these, non-invasive brain stimulation such as transcranial direct current stimulation (tDCS) promotes neuroplasticity in injured brains, with fewer side effects and risks than invasive, implanted approaches such as deep-brain stimulation.

NCT07599774 · Official ClinicalTrials.gov record · Carle Foundation Hospital

Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S.

NCT07602166 · Official ClinicalTrials.gov record · Vanderbilt University Medical Center

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.

NCT07626411 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

Trial fibrillation (AF) is the most common cardiac arrhythmia worldwide, and its prevalence continues to rise. AF is associated with serious complications, including embolic strokes, heart failure, and mortality.

NCT07648329 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire Dijon

The NEWLINE trial is a multicenter, randomly assigned, open-label, blinded endpoint (PROBE) trial evaluating whether added on top of your current treatment low-dose intra-arterial alteplase administered immediately after successful endovascular thrombectomy improves functional outcomes in adults with acute ischemic stroke due to anterior circulation large vessel occlusion. Eligible participants achieving successful reperfusion (eTICI 2b-3) within 24 hours of symptom onset will be randomly assigned 1:1 to receive intra-arterial alteplase plus standard care or standard care alone.

NCT07727395 · Official ClinicalTrials.gov record · 115 People's Hospital

By doing this study, investigators hope to learn how electrical stimulation can improve human movement, biomechanics, and function and to gather information on the safety and effectiveness of an implanted electrical stimulation system after paralysis from spinal cord injury, stroke, multiple sclerosis, and traumatic brain injury.

NCT07738978 · Official ClinicalTrials.gov record · Louis Stokes VA Medical Center

This multicenter, prospective, and treatment diagnostic accuracy study enrolls patients undergoing thrombectomy with intraoperative cerebral autoregulation monitoring and follows them up at predefined time points up to 90 days post-enrollment.This study aims to evaluate a monitoring system based on cerebral autoregulation function and explore its predictive value for adverse neurological outcomes at the ultra-early stage following mechanical thrombectomy.

NCT07747701 · Official ClinicalTrials.gov record · Beijing Shijitan Hospital, Capital Medical University

PREMAP invites residents of the Eloisa region (South Savo, Finland) turning 45, 50, or 55 years of age in 2026 to undergo a blood-based NMR metabolomics risk assessment for five interlinked cardio-renal-metabolic conditions (type 2 diabetes, coronary heart disease/myocardial infarction, stroke/cardiovascular disease, chronic kidney disease, and fatty liver disease), alongside a mental wellbeing assessment (WHO-5 Well-Being Index). Based on this risk profile, participants are classified as low, moderate, or high multi-disease risk.

NCT07820800 · Official ClinicalTrials.gov record · University of Eastern Finland

The goal of this study is to find out whether a comprehensive management program that uses a smart bracelet and a mobile app can help people who have had an ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain) to prevent another stroke. The investigators also want to see whether this program helps with controlling blood pressure, blood sugar, and blood lipids, as well as with taking medications correctly, improving daily habits, and supporting emotional well-being.

NCT07825311 · Official ClinicalTrials.gov record · Affiliated Hospital of Nantong University

This study wants to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to dummy treatment (placebo) in adults who have plaque buildup in their arteries or are at high risk of developing it.

NCT07839936 · Official ClinicalTrials.gov record · Verve Therapeutics, Inc.

This study is being done to learn how information from blood tests, medical records, and wearable devices that track sleep, activity, and heart rate can help predict how people recover after a concussion. The goal is to improve how doctors monitor recovery and give patients better information about what to expect after a head injury.

NCT07858266 · Official ClinicalTrials.gov record · University of Michigan

Embodiment is an important aspect of virtual reality because it affects how natural and engaging the experience feels and can influence performance and learning in VR-based applications, including rehabilitation. In VR, embodiment refers to the extent to which a person feels that a virtual body (avatar) is their own and under their control.

NCT07870044 · Official ClinicalTrials.gov record · IRCCS Eugenio Medea

Perinatal stroke is a rare condition affecting approximately 20-40 births per 100,000. It may be ischemic or hemorrhagic and can occur before or around birth, with diagnosis sometimes delayed until motor or cognitive symptoms emerge.

NCT07898397 · Official ClinicalTrials.gov record · University Hospital, Strasbourg, France

The goal of this clinical trial is to measure the how well it works of a 5-day short-course external trigeminal nerve stimulation (eTNS) regimen in patients with acute ischemic stroke. The main questions it aims to answer are whether a 5-day eTNS intervention can significantly improve the neurological response rate at Day 30 compared to sham stimulation, and whether this short-course treatment yields sustained improvements in neuropsychiatric symptoms (depression, anxiety, and insomnia) over a 90-day follow-up period.

NCT07911605 · Official ClinicalTrials.gov record · Xidian University

The I-FACE project aims to develop and validate a battery to assess famous-face recognition in people with neurodegenerative diseases and stroke. It will examine face naming, familiarity, and semantic knowledge, establish norms for the Italian population, and test how well the measures identify recognition difficulties in patients with frontotemporal dementia, Alzheimer's disease, and stroke.

NCT07911878 · Official ClinicalTrials.gov record · Istituti Clinici Scientifici Maugeri SpA

The ELATE study is a prospective, watch-and-measure (no experimental treatment required) study designed to measure the clinical outcomes and safety profile of endovascular thrombectomy compared with best medical treatment alone in patients presenting with acute ischemic stroke due to anterior large vessel occlusion within 24 to 72 hours from stroke onset or last known well.

NCT07922317 · Official ClinicalTrials.gov record · 115 People's Hospital

Stroke is a leading cause of death and adult disability. Stroke care is still limited by fragmented care pathways, non-standardised diagnostic work-up and follow-up, and local, non-interoperable data systems across the pre-hospital, in-hospital and post-hospital settings.

NCT07924371 · Official ClinicalTrials.gov record · Hospital Universitari Vall d'Hebron Research Institute

Executive functions help people initiate, organize, monitor, and complete everyday activities. Difficulties with these functions are common after acquired brain injury and may also occur in people with long-term pain.

NCT07924774 · Official ClinicalTrials.gov record · Karolinska Institutet

This study wants to measure the safety and preliminary effectiveness of the N1 System, a fully implanted brain-computer interface placed in the motor cortex with the R1 Robot. The study builds on knowledge gained in a previous clinical investigation of this system.

NCT07929792 · Official ClinicalTrials.gov record · Neuralink Corp